Lelli G, Guaraldi M, Canova N, Casadio M, Pannuti F
Oncology Division S. Orsola-Malpighi Hospital, Bologna, Italy.
J Chemother. 1990 Dec;2(6):401-4. doi: 10.1080/1120009x.1990.11739053.
A group of 28 patients with advanced non-small cell bronchogenic carcinoma (NSCBC) entered a phase II study on cisplatin (60 mg/m2, day 1) plus etoposide 120 mg/m2, day 1 to 3), every 3 weeks, in combination with lonidamine (150 mg p.o. t.i.d. continuously from day 1). Seven out of twenty-seven (26%) evaluable patients obtained a partial remission (median duration 22 weeks, range 7-47). Although the side effects were mild, three patients stopped the therapy because of them. Median survival was 14 months, range 2-19. Further studies are necessary to clarify the role of "biochemical modulators" in NSCBC.
一组28例晚期非小细胞支气管癌（NSCBC）患者进入一项II期研究，使用顺铂（60mg/m²，第1天）加依托泊苷（120mg/m²，第1至3天），每3周一次，并联合氯尼达明（从第1天起口服150mg，每日3次）。27例可评估患者中有7例（26%）获得部分缓解（中位持续时间22周，范围7 - 47周）。虽然副作用较轻，但有3例患者因副作用停止治疗。中位生存期为14个月，范围2 - 19个月。有必要进行进一步研究以阐明“生化调节剂”在NSCBC中的作用。
